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TOTAL thymectomy markedly reduces the high incidence of spontaneous
lymphomas in certain strains of mice (McEndy, Boon and Furth, 1944; Law and
Miller, 1950a). A similar effect is seen in mice in which the disease can be induced
by ionizing radiations (Kaplan, 1950), carcinogenic hydrocarbons (Law and
Miller, 1950b) or the inoculation at birth of cell-free leukaemic extracts (Gross,
1959 ; Levinthal, Buffett and Furth, 1959 ; Miller, 1959a, 1959c). Thymectomy
has no effect on radiation-induced myeloid leukaemia in RF mice (Upton et al.,
1958) suggesting that the leukaemogenic influence of the thymus is specific for
lymphoid tissues. There are no differences between thymectomized and control
groups of mice in weight curves, breeding behaviour or susceptibility to common
laboratory infections. Reduction of leukaemia incidence by thymectomy does
not seem, therefore, to be related to other factors affecting the general health of
the animals (Law and Miller, 1950a, 1950b).
Subcutaneous grafts of autologous or isologous thymus in thymectomized mice
restore the potentiality of developing the disease, whether this be spontaneous,
induced by carcinogen (Law and Miller, 1950a, 1950b) or by irradiation (Kaplan
et al., 1956).
The work to be reported here shows that while thymectomy prevents the de-
velopment ofthe disease following inoculation ofleukaemic filtrate, thymusgrafting
as late as 6 months after thymectomy restores the potentiality for leukaemia
development in mice inoculated at birth with cell-free filtrates. A preliminary
account of this work has been given elsewhere (Miller, 1959b).
MATERIALS AND METHODS
The strains C3Hf/PW, C3Hf/Gs, CBA/H and Aki (Miller, 1960) were used.
Filtrates were prepared in the same way and from the same sources as described
elsewhere (Miller, 1960). The route of inocualtion and the doses given were also
the same.
Thymectomy was usually performed at 4 weeks of age. The thymus was
removed by suction through an incision in the neck and thoracic wall extending to
the level of the second rib. Thymus grafting was performed by introducing one
whole thymus with a trocar and cannula into the subcutaneous tissues of the right
or left axilla. Donor and recipient mice were always of the same sex and the age
ofthe donor varied from 1 to 30 days accordin-g to the experiment. Strict asepsis
was observed during the grafting procedure.J. F. A. P. MILLER
EXPERIMENTAL
Three experiments were set up as follows:
Experiment I. Mice of all 4 strains were inoculated at birth with a filtrate of
leukaemic tissue. At 4 weeks of age about half the inoculated mice were thymec-
tomized. Some of the thymectomized mice received a further inoculation of
leukaemic filtrate after thymectomy.
Experiment II.-Normal mice of the C3Hf/Gs strain were thymectomized at
about 4 weeks of age and received from 1 day to 1 month after thymectomy a
subcutaneous thymus graft. The thymuses were obtained either from normal
newborn C3Hf/Gs mice (Group I) or from C3Hf/Gs mice between 5 and 30 days
of age that had themselves been inoculated at birth with Passage A filtrate
(Group II).
Experiment III.-Two groups of mice were studied: the first was inoculated
with leukaemic filtrates soon after birth and thymectomized 4 weeks later, and
the second was first thymectomized at about 4 weeks andinoculated withleukaemic
filtrate just after thymectomy. The mice in both groups were grafted sub-
cutaneously with day-old thymuses from normal C3Hf/Gs mice. These grafts
were performed from 1 day to 6 months after thymectomy in the first group, and
from 1 to 2 months after thymectomy in the second group.
RESULTS
Experiment I. The development of lymphocytic leukaemia in thymectomized mice
inoculated at birth with leukaemicfiltrates (Table I)
Thymectomy prevented leukaemia in all but 3 Aki mice of the strains tested.
This was particularly striking in the C3Hf/Gs strain where Passage A inoculation
into mice at or soon after birth was followed by 100 per cent leukaemias in non-
thymectomized littermates. Further inoculation of extracts after thymectomy
did not raise the incidence of leukaemia in thymectomized hosts. The incidence
TABLE I.-Experiment I.-Incidence of Lymphocytic Leukaemia
in Thymectomized Mice
Mice with
lymphocytic leukaemia*
Filtrate given Number Age
Strain at birth Thymus in group Number in months Per cent
C3Hf/PW . Ak leukaemic fIntact 113 . 20 7-14 17-7
or Passage A 'Removedt 59 . 0 0
C3Hf/Gs . Passage A {ntactdt 45 45 2-4 100 Removedt 38 0 0
CBA/H . Ak leukaemic fIntact 71 5 6-15 7 CBA/H Ak ~~~~~Removed 28 0
rIntact . 69 . 47 3-6 78.2
Aki . Ak leukaernic . 7 9-10
LRemoved . 62 . 3 3, 6 and 10 4-8
* Survivors are over 12 months of age.
t Some of these mice received further inoculations of leukaemic filtrate after thymectomy.
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of spontaneous leukaemia in untreated mice of the strains used here has been
reported elsewhere (Miller, 1960).
Experiment II.-The development of lymphoid tumours in thymuses grafted to
thymectomized mice (Table II)
The fate ofthymuses grafted to normal hosts was examined. Thymuses taken
from normal donors did not develop lymphoid tumours (Group I). On the other
hand, thymuses taken from donors which had themselves been inoculated with
leukaemic extracts at birth became malignant in some of the uninoculated hosts
three to five months after grafting (Group II).
TABLE II.-Experiment II.-Incidence of Lymphoid Tumours in Thymuses
Grafted to Thymectomized C3Hf/Gs Mice
Donor C3Hf/Gs*
, I Host C3Hf/Gst
Age (in i,
,
days) of Age of Mice with lymphoid tumours
Treatment thymus Number host at ,
given at when of mice grafting Age
Group birth grafted grafted (months) Number in months Per cent
I None 1 . 20 1-2 . 0 0
II Passage A 5-9 10 2 3 5-7 30 II . Pasage A l10-30 * 17 2 . 10 5-6 58-4
* Donors in Group I were not inoculated. Donors in Group II received Passage A filtrate at
birth.
t Hosts in either group were not inoculated with filtrates. They were all thymectomized at
1 month of age.
Experiment III.-The development of lymphoid tumours in normal thymuses grafted
to thymectomized hosts inoculated with leukaemicfiltrate (Table III)
The fate of thymuses from normal donors was studied in inoculated thymec-
tomized hosts. About half these thymuses developed lymphoid tumours when
introduced as late as 6 months after thymectomy and almost all became malignant
when grafted within three months after thymectomy (Group I). Lymphoid
tumours were diagnosed from 2 to 4 months after grafting.
Thymuses introduced into hosts inoculated after thymectomy also developed
lymphoid tumours, but only in one-third of the mice (Group II).
TABLE III.-Experiment III.-Incidence of Lymphoid Tumours in Thymuses
Grafted to C3Hf/Gs Mice Inoculated with Leukaemic Filtrates
Age of hosts
Filtrate when grafted
Group* Strain given (months)t
{C/.e 23I I . C3Hf/Gs . Passage A 237
Number
of
mice
10
18
12
11
Mice with lymphoid tumours
Age
Number in months Per cent
10 3-4 100
15 3-5 83-3
9 5-8 75
6 9-11 54-5
II . C3Hf/Gs . Passage A . 2-3 . 9 . 3 7-8 33-3
* Mice in Group I were inoculated at birth and later thymectomized. Mice in Group II were
thymectomized at 24 days and inoculated between 35 and 40 days.
t All the mice were thymectomized at 24 to 30 days of age and received day-old thymuses from
uninoculated healthy isologous mice.
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Transplantation
The thymomas could be transplauted in all cases to untreated 1- to 2-months-
old C3Hf/Gs mice.
In the majority of cases, the tumours in Experiments II and III appeared at
first to be confined to the subcutaneous spaces where the thymus had been grafted.
At this stage the spleens from these animals did not produce leukaemia after
transplantation. Later, dissemination took place and generalized leukaemia
became evident in the thymus grafted hosts. These transplantation studies are
still in progress.
DISCUSSION
Our results confirm the previous findings that thymectomy prevents the
development of lymphomas in mice inoculated with leukaemic filtrates (Gross,
1959; Levinthal et al., 1959; Miller, 1959a). They show, in addition, that the
potentiality for leukaemia development is still present in the inoculated thymec-
tomized host, and that normal thymuses can express this potentiality when grafted
to a subcutaneous site in the inoculated thymectomized host as late as 6 months
after thymectomy.
Thymectomy might prevent the development of leukaemia following iniocula-
tion of leukaemic filtrates by effecting removal of:
(1) The source of the leukaemic agent;
(2) the site of multiplication of the agent;
(3) the cells most susceptible to leukaemic transformationi
(4) the source of a humoral factor involved in leukaemogenesis.
(1) In the present experiments, normal thymuses grafted in thymectomized
inoculated hosts as late as 6 months after thymectomy developed lymphoid
tumours. It cannot be maintained, therefore, that thymectomy prevents leuk-
aemia development in inoculated mice by removing either the source of the
leukaemic agent or the site where the agent is principally stored. This does not
exclude the possibility that the thymus may contain some ofthe agent in inoculated
mice (Gross, 1959) but it does exclude the suggestion that the thymus is the only
source of the agent. It follows that the agent might be recoverable from tissues
of inoculated hosts up to 6 or more months after thymectomy. Experiments are
now in progress to determine whether this can be done.
(2) It ispossible that the leukaemic agent must reach a critical concelntration to
produce leukaemia in its host. If so, the fact that no lymphoid tumour occurred
in inoculated thymectomized mice until a thymus graft was introduced can be
interpreted to mean that the agent multiplies satisfactorily only in thymus tissue.
(3) In every case ofleukaemia following the inoculation ofleukaemic filtrates
the thymus was involved, and in some cases it was the sole organ involved. The
results obtained in Experiment II show that cells capable of leukaemic transfor-
mation are present in the thymus as early as 5 to 10 days after the inoculation of
leukaemic filtrates. Removal of such a potentially malignant focus would thus
prevent the development of the disease. Thymus involvement in C58 mice and
in DBA/2 mice painted with methylcholanthrene is, however, very rare (Law and
Miller, 1950a, 1950b) and yet the disease can be prevented by thymectomy. It
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is difficult to assume that such a procedure, in this case, simply acts by removing
the cells most susceptible to leukaemic transformation.
The evidence obtained from the present work is not sufficient to decide for or
against any or both ofthese last two possible explanations. The fact that thymus
grafted to inoculated thymectomized hosts develops lymphoid tumours can be
taken as supporting evidence for either of these hypotheses.
(4) Our results do not exclude the possibility that a humoral factor might be
involved in leukaemogenesis in hosts that are conditioned either by irradiation,
or chemical carcinogens, or the inoculation of leukaemic filtrates. The possibility
of a non-cellular factor from the thymus exerting an influence in the leukaemo-
geinic process has been stressed by Law (Law and Miller, 1950a; Law and Potter,
1956), and Metcalf (1958), who suggests that this factor is his thymic lymphocy-
tosis stimulating factor which he has showni to stimulate lymphocyte proliferation
in the mouse.
SUM-MARY
1. The effect of thymnectomy and thymus grafting on the leukaemogenic
activity of cell-free leukaemic extracts has been investigated.
2. No leukaemia occurred in 59 C3Hf/PW, 38 C3Hf/Gs and 28 CBA/H mice
inoculated at birth with leukaemic filtrates and thymectomized at 4 weeks of age.
The incidence of leukaemia in non-thymectomized inoculated mice of the same
strains was 17-7 per cent of 113 C3Hf/PW mice, 100 per cent of 45 C3Hf/Gs mice
and 7 per cent of 71 CBA/H mice.
3. Only 3 leukaemias occurred in a group of 62 thymectomized Aki mice which
were inioculated at birth with leukaemic filtrates. The incidence of the disease in
69 non-thymectomized inoculated Aki mice was 78 2 per cent the majority of the
mice succumbing between 3 and 6 months of age.
4. Thymuses from normal day-old C3Hf/Gs mice grafted to normal adult
thymectomized C3Hf/Gs mice did not develop lymphoid tumours or induce
leukaemia in their hosts. From 30 to 60 per cent of thymuses from 5 to 30 days
old C3Hf/Gs mice inoculated at birth with leukaemic filtrate (Passage A) deve-
loped lymphoid tumours when grafted to normal uninoculated thymectomized
C3Hf/Gs mice.
5. Thymuses from normal, uninoculated, day-old, C3Hf/Gs mice were grafted
to adult thymectomized C3Hf/Gs mice which had themselves been inoculated at
birth with Passage A filtrate. From 50 to 100 per cent of these thymuses deve-
loped lymphoid tumours in inoculated mice grafted from 1 day to as late as 6
months after thymectomy.
6. The implications of these results are discussed. It is concluded that the
potentiality for leukaemia development is still present in inoculated thymecto-
mized hosts for many months after thymectomy and that thymus grafting at any
time will express this potentiality in full.
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